{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:44:10Z","timestamp":1793295850394,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020841","name":"Envision","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020841","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007659","name":"Bayer Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.xkme.2025.101133","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:43:20Z","timestamp":1760003000000},"page":"101133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["New and Emerging Nonimmunosuppressive Drug Therapies for Primary Adult Glomerular Diseases"],"prefix":"10.1016","volume":"7","author":[{"given":"Vladimir","family":"Mushailov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3157-5141","authenticated-orcid":false,"given":"Jai","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xkme.2025.101133_bib1","series-title":"Glomerulonephritis","author":"Kazi","year":"2023"},{"key":"10.1016\/j.xkme.2025.101133_bib3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.xkme.2025.101133_bib4","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/ndt\/gfq665","article-title":"The incidence of primary glomerulonephritis worldwide: a systematic review of the literature","volume":"26","author":"McGrogan","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.xkme.2025.101133_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpg.2021.101757","article-title":"Immunosuppressive drugs modes of action","volume":"54-55","author":"Meneghini","year":"2021","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.xkme.2025.101133_bib6","series-title":"Encyclopedia of Infection and Immunity","first-page":"726","article-title":"Immunosuppressive drugs","author":"Hussain","year":"2022"},{"key":"10.1016\/j.xkme.2025.101133_bib7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.xkme.2025.101133_bib8","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/ndt\/gfab335","article-title":"Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial","volume":"37","author":"Wheeler","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.xkme.2025.101133_bib9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","article-title":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial","volume":"12","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.xkme.2025.101133_bib10","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xkme.2025.101133_bib11","series-title":"FILSPARI (sparsentan) (package insert)","year":"2023"},{"key":"10.1016\/j.xkme.2025.101133_bib12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s40265-023-01864-x","article-title":"Sparsentan: first approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.xkme.2025.101133_bib13","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2409415","article-title":"Atrasentan in patients with IgA nephropathy","volume":"392","author":"Heerspink","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xkme.2025.101133_bib14","series-title":"VANRAFIA (atrasentan) (package insert)","year":"2025"},{"key":"10.1016\/j.xkme.2025.101133_bib15","article-title":"WCN24-1506: efficacy and safety of iptacopan in patients with IgA nephropathy: interim results from the phase 3 APPLAUSE-IGAN study","volume":"9","author":"Perkovic","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.xkme.2025.101133_bib16","series-title":"FABHALTA (iptacopan) (package insert)","year":"2024"},{"key":"10.1016\/j.xkme.2025.101133_bib17","series-title":"TARPEYO (budesonide) (package insert)","year":"2021"},{"key":"10.1016\/j.xkme.2025.101133_bib18","series-title":"IgA nephropathy (Berger disease)","author":"Rout","year":"2024"},{"key":"10.1016\/j.xkme.2025.101133_bib19","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3389\/fimmu.2019.01809","article-title":"Immunological pathogenesis of membranous nephropathy: focus on PLA2R1 and its role","volume":"10","author":"Liu","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.xkme.2025.101133_bib20","article-title":"Rout P, Hashmi M, Baradhi KM. Focal segmental glomerulosclerosis","year":"2024","journal-title":"Treasure Island, FL: StatPearls Publishing;"},{"key":"10.1016\/j.xkme.2025.101133_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100826","article-title":"A review of focal segmental glomerulosclerosis classification with a focus on genetic associations","volume":"6","author":"Bonilla","year":"2024","journal-title":"Kidney Med"},{"key":"10.1016\/j.xkme.2025.101133_bib22","doi-asserted-by":"crossref","first-page":"ii28","DOI":"10.1093\/ckj\/sfad198","article-title":"Targeting complement in IgA nephropathy","volume":"16","author":"Caravaca-Fontan","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.xkme.2025.101133_bib23","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.xkme.2025.101133_bib24","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.kint.2024.05.015","article-title":"The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"106","author":"Vivarelli","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.xkme.2025.101133_bib25","series-title":"Membranous nephropathy","author":"Alok","year":"2023"},{"key":"10.1016\/j.xkme.2025.101133_bib26","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfad228","article-title":"Novel biomarkers and pathophysiology of membranous nephropathy: PLA2R and beyond","volume":"17","author":"Murtas","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.xkme.2025.101133_bib27","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41467-023-36068-0","article-title":"The classical pathway triggers pathogenic complement activation in membranous nephropathy","volume":"14","author":"Seifert","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.xkme.2025.101133_bib28","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s00467-006-0357-2","article-title":"Pathophysiology of focal segmental glomerulosclerosis","volume":"22","author":"Reidy","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.xkme.2025.101133_bib29","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1111\/j.1523-1755.2005.09911.x","article-title":"The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease","author":"Remuzzi","year":"2005","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.xkme.2025.101133_bib30","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJM199811123392007","article-title":"Pathophysiology of progressive nephropathies","volume":"339","author":"Remuzzi","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xkme.2025.101133_bib31","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1152\/physrev.00038.2017","article-title":"Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology","volume":"98","author":"Forrester","year":"2018","journal-title":"Physiol Rev"},{"key":"10.1016\/j.xkme.2025.101133_bib32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3892\/etm.2023.11852","article-title":"Role of arterial hypertension and angiotensin II in chronic kidney disease (review)","volume":"25","author":"Maranduca","year":"2023","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.xkme.2025.101133_bib33","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00125-023-06031-1","article-title":"Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists","volume":"67","author":"Savarese","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.xkme.2025.101133_bib34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/MNH.0000000000000185","article-title":"Endothelin-1 and the kidney: new perspectives and recent findings","volume":"25","author":"De Miguel","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.xkme.2025.101133_bib35","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/HYPERTENSIONAHA.123.21716","article-title":"Endothelin system in hypertension and chronic kidney disease","volume":"81","author":"Schiffrin","year":"2024","journal-title":"Hypertension"},{"key":"10.1016\/j.xkme.2025.101133_bib36","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1042\/CS20240249","article-title":"Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease","volume":"138","author":"Kohan","year":"2024","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.xkme.2025.101133_bib37","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/ndt\/gfad215","article-title":"Tubular toxicity of proteinuria and the progression of chronic kidney disease","volume":"39","author":"Makhammajanov","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.xkme.2025.101133_bib38","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1053\/j.ackd.2014.11.006","article-title":"Sodium retention and volume expansion in nephrotic syndrome: implications for hypertension","volume":"22","author":"Ray","year":"2015","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.xkme.2025.101133_bib39","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1681\/ASN.2005010055","article-title":"Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene","volume":"16","author":"Wharram","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.xkme.2025.101133_bib40","series-title":"Proteinuria. Treasure Island, FL","author":"Haider","year":"2023"},{"key":"10.1016\/j.xkme.2025.101133_bib41","article-title":"Proteinuria as a therapeutic target in advanced chronic kidney disease: a retrospective multicenter cohort study","volume":"6","author":"Chen","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.xkme.2025.101133_bib42","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030131","article-title":"Albuminuria: an underappreciated risk factor for cardiovascular disease","volume":"13","author":"Barzilay","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.xkme.2025.101133_bib43","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.xkme.2025.101133_bib44","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.xkme.2025.101133_bib45","series-title":"JARDIANCE (empagliflozin) (package insert)","year":"2023"},{"key":"10.1016\/j.xkme.2025.101133_bib46","series-title":"FARXIGA (dapagliflozin) (package insert)","year":"2024"},{"key":"10.1016\/j.xkme.2025.101133_bib47","series-title":"Kerendia (finerenone) (package insert)","year":"2025"},{"key":"10.1016\/j.xkme.2025.101133_bib48","series-title":"OZEMPIC (semaglutide) (package insert)","year":"2025"},{"key":"10.1016\/j.xkme.2025.101133_bib49","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/ndt\/gfae132","article-title":"Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial","volume":"40","author":"Heerspink","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.xkme.2025.101133_bib50","series-title":"Sodium-glucose transport protein 2 (SGLT2) inhibitors","author":"Padda","year":"2023"},{"key":"10.1016\/j.xkme.2025.101133_bib51","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xkme.2025.101133_bib52","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xkme.2025.101133_bib53","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xkme.2025.101133_bib54","series-title":"INVOKANA (canagliflozin) (package insert)","year":"2022"},{"key":"10.1016\/j.xkme.2025.101133_bib55","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xkme.2025.101133_bib56","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa2308550","article-title":"Sparsentan versus irbesartan in focal segmental glomerulosclerosis","volume":"389","author":"Rheault","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xkme.2025.101133_bib57","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xkme.2025.101133_bib58","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3390\/medicina55060233","article-title":"GLP-1 receptor agonists and kidney protection","volume":"55","author":"Greco","year":"2019","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.xkme.2025.101133_bib59","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.3390\/jcm10173955","article-title":"GLP-1 receptor agonists in diabetic kidney disease: from physiology to clinical outcomes","volume":"10","author":"Rojano Toimil","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.xkme.2025.101133_bib60","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.ajkd.2024.08.002","article-title":"Glucagon-like peptide-1 receptor agonists: new evidence of kidney and cardiovascular protection from the FLOW and SELECT trials","volume":"85","author":"Taal","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.xkme.2025.101133_bib61","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xkme.2025.101133_bib62","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xkme.2025.101133_bib63","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.ekir.2022.07.002","article-title":"Challenges in diagnosis and management of glomerular disease in resource-limited settings","volume":"7","author":"Ramachandran","year":"2022","journal-title":"Kidney Int Rep"}],"updated-by":[{"DOI":"10.1016\/j.xkme.2026.101281","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000}},{"DOI":"10.1016\/j.xkme.2026.101281","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000}}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525001694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525001694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T13:17:35Z","timestamp":1775308655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059525001694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":62,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2590059525001694"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2025.101133","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New and Emerging Nonimmunosuppressive Drug Therapies for Primary Adult Glomerular Diseases","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2025.101133","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101133"}}